RecruitingAdvanced Solid Tumors
A Trial to Investigate the Safety of E303 in Participants With Advanced Refractory Solid Tumors
Eligible age
18+ yrs
Accepts
All genders
Locations
2 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
This is a Phase I trial to evaluate the safety, tolerability and efficacy of nectin-4 targeting antibody-drug conjugate (SBE303) in participants with advanced solid tumors
Sponsor: Samsung Bioepis Co., Ltd.
You may qualify if…
- ✓ Histologically-confirmed, locally advanced (unresectable) or metastatic solid tumors with recurrence or progression during or after standard therapy, intolerance to standard therapy, refused to receive standard therapy, or for whom no standard therapy is available.
You may not qualify if…
- ✕ Have spinal cord compression or clinically active central nervous system metastases
- ✕ Have leptomeningeal disease
- ✕ Have thromboembolic or clinically significant bleeding events
- ✕ Have significant cardiovascular disease
- ✕ Have an active autoimmune disease
Where it's recruiting
Source: ClinicalTrials.gov · NCT07524348 · last updated 2026-10-01